TrialOPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Trial details
- Registry ID
- NCT04757610
- Phase
- Phase 3
CKDXF
Opthea Limited
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
0Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)NCT04757610 | Opthea Limited | Phase 3 | Terminated | 2025-03-31Actual |
| OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)NCT04757636 | Opthea Limited | Phase 3 | Terminated | 2025-03-31Actual |
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
Trial details
- Registry ID
- NCT04757636
- Phase
- Phase 3
Latest recorded trial changes
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.